Vontobel Swiss Wealth Advisors AG Invests $303,000 in Amgen Inc. (AMGN)
Vontobel Swiss Wealth Advisors AG purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent filing with the SEC. The firm purchased 2,210 shares of the medical research company’s stock, valued at approximately $303,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its position in Amgen by 0.6% in the first quarter. Acadian Asset Management LLC now owns 8,268 shares of the medical research company’s stock worth $1,239,000 after buying an additional 51 shares during the period. P.R. Herzig & Co. Inc. raised its position in Amgen by 107.7% in the first quarter. P.R. Herzig & Co. Inc. now owns 7,975 shares of the medical research company’s stock worth $1,196,000 after buying an additional 4,135 shares during the period. First Financial Corp IN raised its position in Amgen by 1.9% in the first quarter. First Financial Corp IN now owns 3,573 shares of the medical research company’s stock worth $536,000 after buying an additional 65 shares during the period. McQueen Ball & Associates Inc. raised its position in Amgen by 1.7% in the first quarter. McQueen Ball & Associates Inc. now owns 10,642 shares of the medical research company’s stock worth $1,596,000 after buying an additional 182 shares during the period. Finally, Sigma Planning Corp raised its position in Amgen by 7.6% in the first quarter. Sigma Planning Corp now owns 6,278 shares of the medical research company’s stock worth $941,000 after buying an additional 442 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 166.81 on Friday. The firm has a 50-day moving average of $171.68 and a 200-day moving average of $161.02. The firm has a market cap of $124.83 billion, a PE ratio of 17.07 and a beta of 0.87. Amgen Inc. has a 52 week low of $138.06 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. The firm earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.57 earnings per share. On average, analysts expect that Amgen Inc. will post $11.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 40.90%.
AMGN has been the topic of a number of recent analyst reports. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $159.50 price target on the stock. in a research report on Tuesday, June 7th. Bank of America Corp. restated a “hold” rating and issued a $182.00 price target on shares of Amgen in a research report on Wednesday, June 8th. BMO Capital Markets restated an “outperform” rating and issued a $186.00 price target on shares of Amgen in a research report on Thursday, June 9th. Leerink Swann reiterated a “market perform” rating and set a $186.00 target price on shares of Amgen in a research report on Thursday, June 9th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and set a $202.00 target price on shares of Amgen in a research report on Wednesday, June 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and a consensus target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.